Zacks Investment Research lowered shares of Vistagen Therapeutics (NASDAQ:VTGN) from a hold rating to a sell rating in a research note released on Wednesday.

According to Zacks, “VistaGen Therapeutics, Inc. is a biotechnology company. It is engaged in developing and commercializing product candidates for diseases and disorders involving the central nervous system. The company’s lead product candidate consists of AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder. VistaGen Therapeutics, Inc. is headquartered in South San Francisco, California. “

VTGN has been the topic of several other reports. Oppenheimer set a $6.00 price target on Vistagen Therapeutics and gave the stock a buy rating in a research report on Sunday, November 4th. Maxim Group set a $6.00 price target on Vistagen Therapeutics and gave the stock a buy rating in a research report on Wednesday, October 3rd. Finally, ValuEngine upgraded Vistagen Therapeutics from a hold rating to a buy rating in a research report on Thursday, November 1st. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus target price of $8.30.

VTGN traded down $0.04 on Wednesday, hitting $2.00. 102,458 shares of the company were exchanged, compared to its average volume of 557,919. Vistagen Therapeutics has a 12 month low of $0.69 and a 12 month high of $2.65. The firm has a market cap of $64.29 million, a price-to-earnings ratio of -1.80 and a beta of -1.53.

Vistagen Therapeutics (NASDAQ:VTGN) last posted its quarterly earnings results on Monday, October 29th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.13). On average, equities research analysts anticipate that Vistagen Therapeutics will post -1.1 EPS for the current fiscal year.

About Vistagen Therapeutics

VistaGen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder.

Featured Story: Earnings Per Share (EPS) Explained

Get a free copy of the Zacks research report on Vistagen Therapeutics (VTGN)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Vistagen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vistagen Therapeutics and related companies with's FREE daily email newsletter.